![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Estratti |
Permessi |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
MONOCLONAL ANTIBODIES FOR IN VIVO APPLICATIONS - PART II
Minerva Biotecnologica 1998 December;10(4):131-7
Copyright © 1998 EDIZIONI MINERVA MEDICA
lingua: Inglese
Monoclonal antibodies for therapy: current status and future perspectives
Funaro A. 1, Horenstein A. L. 1, Cinti C. 2, Malavasi F. 2
1 Department of Genetic, Biology and Biochemistry, Laboratory of Cell Biology, University of Torino, Torino, Italy; 2 Institute of Biology and Genetics, University of Ancona, Ancona, Italy
This survey is an overview of the applications of murine, humanized, human and recombinant monoclonal antibodies in vivo for diagnostic and therapeutic purposes. Monoclonal antibodies have been applied to the diagnosis and therapy of an array of human diseases; however, effective therapy using unmodified murine antibodies has often been elusive. Recently, monoclonal antibody therapy has been revolutionized by the identification of a number of suitable target molecules and by the development of antibody engineering techniques which have allowed the production of a new generation of molecules characterized by reduced immunogenicity and enhanced targeting ability. More than twenty years after the technique for monoclonal antibodies was devised, clinical data is outlining an increasingly significant role for antibody-based therapy as a versatile and powerful instrument in cancer treatment.